Two glaucoma drugs approved last year, travoprost (Travatan, Alcon) and bimatoprost (Lumigan, Allergan), are associated with higher rates of hyperemia than the more established drug latanoprost (Xalatan, Pharmacia). However, the hyperemia is seldom a clinically significant side effect, according to a sampling of physicians who are familiar with all three drugs.